NIKKEI 225
38,396.63 -836.17 (-2.13%) HANG SENG
16,288.04 -312.42 (-1.88%) CRUDE OIL
85.87 +0.46 (+0.54%) GOLD FUTURES
2,404.10 +21.10 (+0.89%) DOW
37,735.11 -248.13 (-0.65%) Bitcoin GBP
50,704.17 -1,616.39 (-3.09%)
Grifols SA (OZTA.BE)
| Previous close | 8.53 |
| Open | 8.63 |
| Bid | 8.27 x 79100 |
| Ask | 8.97 x 77200 |
| Day's range | 8.55 - 8.79 |
| 52-week range | 6.58 - 15.72 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ReutersSpanish drug maker Grifols will bring in independent directors, chairman tells newspaper
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.
BloombergGrifols Plans First Bond Sale Since Short Seller Attack
(Bloomberg) -- Grifols SA is seeking to issue a new bond, in what would be its first debt deal since coming under attack from a short seller in January.Most Read from BloombergUS Slams Strikes on Russia Oil Refineries as Risk to Oil MarketsUS Core CPI Tops Forecasts Again, Likely Delaying Fed Rate CutsChinese Cement Maker Halted After 99% Crash in 15 MinutesBond Trader Places Record Futures Bet on Eve of Inflation DataApple’s India iPhone Output Hits $14 Billion in China ShiftThe Barcelona-based
ReutersGrifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake
Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday. Grifols did not specify the amount due next year. Since January, the Spanish drug maker's debt sustainability has been questioned by short seller Gotham City Research.
